RECENT NEWS

In a significant advancement for cancer immunotherapy, researchers have developed a novel approach using mRNA-encoded nanobodies that effectively combat colorectal cancer in preclinical models.

Cancer diagnostics firm GRAIL has announced the topline results from the landmark, randomised, controlled NHS-Galleri trial, which evaluated annual multi-cancer screening with the Galleri blood test in the NHS over three years in 142,000 demographically representative participants aged 50 to 77.

A new research paper has shown the first evidence of a WHO ‘critical priority’ fungal pathogen becoming more deadly when co-infected with tuberculosis.

Researchers from the University of Southern Denmark have identified a new virus in a common gut bacterium. The virus is found significantly more often in patients with colorectal cancer.

Researchers in Imperial’s Fleming Initiative have been awarded £3 million of new funding through a global programme to help transform the discovery of new antibiotics and tackle the growing threat of antimicrobial resistance (AMR).

New figures from the Medicines and Healthcare products Regulatory Agency (MHRA) show a 17% rise in approved clinical investigations compared with last year, as companies increasingly choose Great Britain to test cutting-edge health technologies.

Syndex Bio, a biotechnology company advancing next‑generation molecular diagnostics, has announced the introduction of its proprietary mcPCR (methyl‑copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) conference in Orlando, Florida.

Bio-Techne has announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union.

People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).

US Biotechnology firm Centivax has announced the start of a Phase 1A clinical trial evaluating Centi-Flu 01, a pan-influenza universal flu vaccine, in healthy volunteers.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on proposals for indefinite recognition of CE-marked medical devices in Great Britain (GB), aimed at protecting patient access and ensuring the continued supply of safe and effective medical technologies.

Power to Disrupt : Leaders in POCT Diagnostics has unveiled the first additions to its speaker lineup. The event takes place in Birmingham on 5 May.

QuidelOrtho has entered a long-term strategic supply agreement with Chinese firm Lifotronic Technology, to expand its global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States.

The Royal College of Pathologists (RCPath) has submitted a response to the Medicines and Healthcare products Regulatory Agency’s (MHRA) call for evidence to help shape the work of the new National Commission on the Regulation of AI in Healthcare.

Dr Sarah Pitt, a virologist and Principal Lecturer in Biomedical Science at the University of Brighton, has been formally inaugurated as President of the Institute of Biomedical Science.

AI-powered pathology firm Path AI has announced an expansion of its support of inflammatory bowel disease clinical trials.

Leica Biosystems has launched the Leica CM1950 Cryostat with DualEcoTec Cooling System, which it says will redefine histology workflows.

Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to cardiovascular disease, providing critical insights on how influenza can damage the heart and increase the risk of a heart attack or other major cardiovascular event.

Waters Corporation has announced it has completed the previously announced combination with the biosciences and diagnostic solutions businesses of Becton, Dickinson and Company (BD).

As preparations for the London Biotechnology Show 2026 continue to gain momentum, Early Bird registrations are now entering their final days. With just a few days remaining, this is the last opportunity to secure delegate access at reduced rates.